These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Figgitt DP; McClellan KJ Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201 [TBL] [Abstract][Full Text] [Related]
3. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Gunasekara NS; Noble S; Benfield P Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792 [TBL] [Abstract][Full Text] [Related]
6. Potential indications for the selective serotonin reuptake inhibitors. Boyer WF Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():5-12. PubMed ID: 1431022 [TBL] [Abstract][Full Text] [Related]
7. Spotlight on paroxetine in psychiatric disorders in adults. Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788 [TBL] [Abstract][Full Text] [Related]
8. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder. Foster RH; Goa KL CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224 [TBL] [Abstract][Full Text] [Related]
9. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457 [TBL] [Abstract][Full Text] [Related]
10. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Pearlstein T Drugs; 2002; 62(13):1869-85. PubMed ID: 12215058 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Pelissolo A Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243 [TBL] [Abstract][Full Text] [Related]
12. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Zohar J; Westenberg HG Acta Psychiatr Scand Suppl; 2000; 403():39-49. PubMed ID: 11019934 [TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277 [TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression]. Semba J Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):79-84. PubMed ID: 10976459 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657 [TBL] [Abstract][Full Text] [Related]
16. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott TA; Seay SM J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636 [TBL] [Abstract][Full Text] [Related]
19. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. Goodwin GM J Clin Psychiatry; 1996; 57 Suppl 4():9-13. PubMed ID: 8636065 [TBL] [Abstract][Full Text] [Related]
20. Psychopharmacology of comorbid obsessive-compulsive disorder and depression. den Boer JA J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]